
Tour de force trial for #osteoarthritis in clinical trials session #ASTRO26 with 13 year follow-up (!) from Russian colleagues show better pain control, less progressive joint deformity, less disability and knee replacements. @ASTRO_org #OA
✓Dad, husband, Radiation Oncologist with Southeast Radiation Oncology and Levine Cancer Institute @atriumhealth @levinecancer. Of course, the opinions are mine

Tour de force trial for #osteoarthritis in clinical trials session #ASTRO26 with 13 year follow-up (!) from Russian colleagues show better pain control, less progressive joint deformity, less disability and knee replacements. @ASTRO_org #OA


I battle the great @DanTrifMD

It’s a beautiful day in #Boston to attend the action packed #ASTRO26 PRO session, particularly the #CNS on margins. Come watch me referee as @joshuapalmermd and @DanTrifMD engage in a vigorous exchange educating us and hopefully still walk away as friends! @ASTRO_org @LevineCancer @wakeforestmed @WakeCancer

Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial thelancet.com/journals/lanep…


Honored to be included in this group that has done so much for our patients, the specialty and ASTRO! @LevineCancer @AtriumHealth @WakeCancer

Congratulations to the class of 2026 ASTRO Fellows! ASTRO is pleased to announce that 39 members will receive the ASTRO Fellow (FASTRO) designation. The 2026 class of Fellows will be officially inducted during the Awards Ceremony at ASTRO's 68th Annual Meeting in Boston. #ASTRO26 Learn more: ow.ly/ZVSC50Ztma9

Excited for the @ASTRO_org Presidential symposium ! @SameerKeoleMD has an action packed slate of fascinating talks on non-malignant disease #ASTRO25

🔔⏰ Welcome to #ASTRO2025 ⏰ 🔔 Honored to sit on the stage in front of a big crowd while we learn from @ChristyCramerMD @stuxrt @joshuapalmermd If you’re on your way get excited, tons of great presentations planned and networking opportunities. And also perfect weather 💪

PRO sessions in full force here at #ASTRO2025 with more brains 🧠 joining for brain reRT @DanTrifMD @joshuapalmermd @ChristyCramerMD @stuxrt

For those East Coast early risers at #ASTRO25 forget the @rydercup and come over and watch the All-Star panel at the PRO session of @DanTrifMD @joshuapalmermd and @ChristyCramerMD and me discuss re-irradiation of #braintumors (and Mets) plus reduce toxicity @ASTRO_org

It was a pleasure working with an all-star team to update the former ACR (now @RadiumSociety) "Appropriate Use" guideline on sinonasal cancer #radonc #hncsm @HeadNeckMD @MargalitMd doi.org/10.1002/hed.28177

Congrats on Dr Michael Chan new Chair of #RadOnc for @wakeforestmed WS Campus). Amazing succesor of #WilliamBlackstock as #ServantLeader, #CNS CA leader/educator/@AtriumHealthWFB Comprehensive Cancer Center @DavidZaasMD #DeanBoulware @JFreischlag

Inspiring retreat at @Kcannonballers for @AtriumHealth @LevineCancer on delivering #LovedOneStandard #CancerCare #BestPlaceToCare @AtriumHealthWFB Comprehensive Cancer Center @LeonMizrachi @stuxrt @confectionsmd @KatherineAnsley @DiannaSHoward @wakeforestmed @PlasmaCellPete

Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer out on Lancet Oncology buff.ly/4huOHek Multicentre, single-arm phase 2 trial evaluated the safety and efficacy of a novel treatment approach for patients with unresectable, locally advanced non-small-cell #LungCancer ( #NSCLC ), involving stereotactic body radiotherapy (SBRT) to the primary tumor, followed by standard chemoradiotherapy to the lymph nodes and consolidation immunotherapy with durvalumab. Sixty-one patients were enrolled, with a median follow-up of 29.5 months. The study reported a 1-year progression-free survival (PFS) of 62.7%, although it did not achieve the primary endpoint of significant improvement over historical controls. Treatment-related grade 3–4 adverse events included decreased neutrophil and white blood cell counts, and treatment-related deaths occurred in 7% of patients. Despite not meeting the primary endpoint, the treatment demonstrated favorable activity and safety profiles, forming the basis for an ongoing randomized phase 3 trial (NRG Oncology LU008). @DrJRadOnc @KMilehamMD @DrChrisCorso @AKesarwala @stuxrt Ping OncoAlert Rad Onc Faculty @MKnoll_MD @HenningWillers @fumikochino @_ShankarSiva @PercyLeeMD @Icro_Meattini @DrChowdharyMD @DrLesterColl @ErinGillespieMD @seanmmcbride @NiuSanford #OncoAlertAF @nataliagandur @acampsmalea @BiagioRicciutMD @yekeduz_emre @HHorinouchi @FadiHaddad_MD @Dr_Ivanoncologo @Abdallah81MD @FernandoOnco @ElisaAgostinett @to_be_elizabeth @bavilima @realbowtiedoc @Erman_Akkus @Lucarecco @GaiaGriguolo @JankovicK